United States: Federal Circuit Hears Arguments In Other Myriad Gene Patents Case

On October 6, 2014, the Federal Circuit heard oral arguments in a case involving the claims of the Myriad gene patents that were not invalidated by the Supreme Court's 2013 decision. The Federal Circuit is reviewing the district court's denial of Myriad's motion for a preliminary injunction against Ambry Genetics Corp., based on the finding that Ambry had "raised a substantial question" as to whether Myriad's "Primer Claims" and "Method Claims" are directed to "patent [in]eligible products of nature and abstract ideas." (You can read more about the district court decision here.) The easiest decision for the Federal Circuit to reach would be to affirm based on the "substantial question" standard without deciding patent eligibility on the merits. As Myriad's counsel suggested, such a decision would leave the biotech industry "at sea" until the case makes it way back to the Federal Circuit again.

The Myriad Claims at Issue

The district court divided the Myriad gene patent claims at issue into the Primer Claims and the Method Claims.

The Primer Claims included claims 16 and 17 of U.S. Patent No. 5,747,282 and claims 29 and 30 of U.S. Patent No. 5,837,492. Claims 16 and 17 of the '282 patent are representative.

16. A pair of single-stranded DNA primers for determination of a nuycleotide [sic] sequence of a BRCA1 gene by a polymerase chin [sic] reaction, the sequence of said primers being derived from human chromosomne sic] 17q, wherein the use of said primers in a polymerase chain reaction results in the synthesis of DNA having all or part of the sequence of the BRCA1 gene.

17. The pair of primers of claim 16 wherin [sic] said BRCA1 gene has the nucleotide sequence set forth in SEQ ID NO:1.

The claimed primers have nucleotide sequences that correspond to fragments of the naturally occurring BRCA1 and BRCA2 sequences. As such, these claims would not be patent eligible under the USPTO's March 4, 2014 Patent Subject Matter Eligibility Guidance.

The Method Claims included claims 7 and 8 of U.S.Patent No. 5,753,441, claim 4 of U.S. Patent No. 6,033,857, claim 5 of U.S. Patent No. 6,951,721, and claims 2 and 4 of U.S. Patent No. 5,654,155. Claim 4 of the '857 patent is representative:

4. The method of claim 2 wherein the detection in the alteration in the germline sequence is determined by an assay selected from the group consisting of (a) observing shifts in electrophoretic mobility of single-stranded DNA on non-denaturing polyacrylamide gels, (b) hybridizing a BRCA2 gene probe to genomic DNA isolated from said tissue sample, (c) hybridizing an allele-specific probe to genomic DNA of the tissue sample, (d) amplifying all or part of the BRCA2 gene from said tissue sample to produce an amplified sequence and sequencing the amplified sequence, (e) amplifying all or part of the BRCA2 gene from said tissue sample using primers for a specific BRCA2 mutant allele, (f) molecularly cloning all or part of the BRCA2 gene from said tissue sample to produce a cloned sequence and sequencing the cloned sequence, (g) identifying a mismatch between (1) a BRCA2 gene or a BRCA2 mRNA isolated from said tissue sample, and (2) a nucleic acid probe complementary to the human wild-type BRCA2 gene sequence, when molecules (1) and (2) are hybridized to each other to form a duplex, (h) amplification of BRCA2 gene sequences in said tissue sample and hybridization of the amplified sequences to nucleic acid probes which comprise wild-type BRCA2 gene sequences, (i) amplification of BRCA2 gene sequences in said tissue sample and hybridization of the amplified sequences to nucleic acid probes which comprise mutant BRCA2 gene sequences, (j) screening for a deletion mutation in said tissue sample, (k) screening for a point mutation in said tissue sample, (l) screening for an insertion mutation in said tissue sample, (m) in situ hybridization of the BRCA2 gene of said tissue sample with nucleic acid probes which comprise the BRCA2 gene.

The claimed methods "involve" a product of nature. As such, their patent eligibility under the USPTO's Guidance would depend on the outcome of the multi-factored analysis laid out in the Guidance.

The Oral Arguments

The appeal has been assigned to a panel consisting of Chief Judge Prost, Judge Clevenger and Judge Dyk. Jonathan Singer from Fish and Richardson P.C. argued for Myriad. Counsel for Ambry did not identify himself on the record, but William Gaede, III from McDermott Will & Emery LLP is named as the lead attorney on the Ambry briefs.

The following is a rough summary of key questions and answers based on my review of the oral argument recording that you can find here.

Judge Prost: Is it your position that you should look at the entire claim? I thought the Supreme Court was quite clear in Myriad: You take away the abstract idea or law of nature, look at the additional steps, and determine whether the additional steps are well-understood, routine, and conventional such that they add nothing significant.

Judge Clevenger: Walk me through "the claim as a whole" analysis ....

Judge Dyk: How does adding conventional steps confer patentability?

Myriad: The BRCA1 probe was not conventional. The BRCA1 probe is part of the invention and had never been used before. .... Myriad did not invent how to make cDNA from a genomic sequence, but the Supreme Court held that the cDNA sequence was patent eligible. The Supreme Court did not hold that you have to invent a new method of making cDNA in order for a cDNA sequence to be patent eligible.

Myriad: The Primer Claims have a utility that is different from what's found in nature–a utility in PCR. That distinguishes them from the bacteria at issue in Funk Brothers.

Judge Clevenger: Isn't the issue before us whether there is a "substantial question" of patent eligibility?

Judge Dyk: Would a district court trial illuminate the issues before us?

Myriad: The main issues are issues of law. .... The biotech community is at sea, and this case is a good one to resolve these issues.

Ambry: A primer is just a segment of DNA, and the Supreme Court held in Myriad that when cDNA is indistinguishable from genomic DNA, it is not patent eligible.

Judge Clevenger: What do primers do in the body? Don't they have a different function?

Ambry: RNA primers help prime the synthesis and replication of DNA and RNA. The district court found that primers perform the task of priming in a way that mirrors and mimics nature –they form the starting point of filling in of subsequent nucleotides of the second strand of DNA.

Judge Dyk: What difference is there if the function is different? That's true in all of the claims that we considered the first time around. When you take a part of the DNA you're going to use it for different functions–for comparisons, for example. .... Function can't be the test, can it? All the other claims would have come out differently–so function can't be the determinant.

Ambry: All other steps in the claims were routine and conventional

Judge Dyk: Do you see a difference between claim 7 and 8 and claim 21 [which was upheld]?

Judge Clevenger: Was the probe new?

Ambry: The Primer Claims are not patent eligible because they are a product of nature, as a segment of naturally occurring DNA.

Judge Clevenger: If the probe were tagged [labeled] would it be eligible?

Ambry: I don't think so.

Judge Clevenger: What can your adversary patent?

Ambry: As discussed in Alice, they could obtain a patent if there was an improvement in the function of the primer or probe over the prior art, or an advancement in the technology.

Judge Dyk: The Supreme Court was concerned about excluding all possible claims that would reward the invention here.

Ambry: They do have claim 21, to the method of using the sequence in an in vitro assay, where there is a new construct made, as in Chakrabarty.

Myriad: Myriad did not invent the basic technique of claim 21, so that can't be the basis for eligibility. The Primer Claims represent an enlargement of utility, which was lacking in Funk Brothers, and which should support eligibility.

Biotech at Sea

If the biotech industry has been at sea since the 2013 Supreme Court decision in Myriad, it might feel storm-tossed after these oral arguments. I'm not sure if I'm more worried about Judge Prost's summary of Myriad's clear directions to consider the claims as a whole by picking them apart, or by Judge Dyk's conviction that a different function can't be the basis for eligibility. Instead of hoping for a rescue at sea, I am left worrying that the biotech industry will be walking the plank after this latest Myriad gene patents case.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions